Clinical Trials
26 trialsNCT07196111 2026-05-28
BAFFR CAR-T Treatment for Relapsed/Refractory B-cell Tumors
Guangzhou Bio-gene Technology Co., Ltd
Phase EARLY_PHASE1 Withdrawn
NCT07453446 2026-05-06
Clinical Study of U29 Injection (CD30-CART) in Patients With CD30-Positive Relapsed/Refractory Lymphoma
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1 Withdrawn
NCT04052061 2025-02-21
QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma
ImmunityBio, Inc.
Phase 1 Withdrawn
NCT03417765 2024-10-24
Safety, Tolerability, PK/PD of FE 203799 in Adults With Lymphomas
VectivBio AG
Phase 1/2 Withdrawn
NCT05431179 2023-04-21
A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Oncternal Therapeutics, Inc
Phase 3 Withdrawn
NCT03370185 2023-02-28
BRIO
SecuraBio
Phase 2 Withdrawn
NCT03359733 2023-02-08
A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor
Calithera Biosciences, Inc
Phase 1 Withdrawn
NCT04891718 2022-07-08
CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia
Presage Biosciences
Phase EARLY_PHASE1 Withdrawn
NCT04464889 2021-10-08
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation
Medigene AG
Phase 1 Withdrawn
NCT02605694 2021-03-17
FRESCO
SecuraBio
Phase 2 Withdrawn
NCT00551239 2020-10-19
Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
CTI BioPharma
Phase 3 Withdrawn
NCT02786485 2020-10-05
Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT
Bellicum Pharmaceuticals
Phase 1 Withdrawn
NCT02800889 2020-01-29
Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer
CTI BioPharma
Phase 1 Withdrawn
NCT02582827 2019-08-28
QUILT-3.014: A Trial of ABI-011 Administered Weekly in Patients With Advanced Solid Tumors or Lymphomas
NantBioScience, Inc.
Phase 1 Withdrawn
NCT02657447 2019-01-10
Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)
Nordic Nanovector
Phase 1 Withdrawn
NCT02545361 2018-08-16
Safety, Tolerability, and Anti-cancer Activity of KAHR-102 (The Study Drug) for the Treatment of Lymphoma Patients
Kahr Medical
Phase 1/2 Withdrawn
NCT02229981 2017-12-07
ABC-102
RedHill Biopharma Limited
Phase 1/2 Withdrawn
NCT03141398 2017-07-26
CGMs
Hamad Medical Corporation
Withdrawn
NCT01244009 2016-11-07
A Study of MK-4827 for the Treatment of Mantle Cell Lymphoma (MK-4827-002)
Tesaro, Inc.
Phase 2 Withdrawn
NCT02780830 2016-09-15
INHIBITOR
AstraZeneca
Phase 1 Withdrawn
NCT02640833 2016-07-26
A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor
AbbVie
Phase 1 Withdrawn
NCT00457574 2013-08-28
Safety and Efficacy of GMX1777 in the Treatment of Refractory Solid Tumors or Lymphomas
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1 Withdrawn
NCT01139359 2012-07-19
Safety Study of Darinaparsin in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) to Treat Lymphoma
Alaunos Therapeutics
Phase 1 Withdrawn
NCT00886496 2012-06-20
Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia
Enzon Pharmaceuticals, Inc.
Phase 1 Withdrawn
NCT01194193 2011-05-16
Preliminary Anti-tumour Activity of mTor Kinase Inhibitor in Advanced Tumours
AstraZeneca
Phase 1 Withdrawn
NCT00298467 2010-04-26
MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma
Bristol-Myers Squibb
Phase 2 Withdrawn